Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Pulse Biosciences, Inc.NASDAQ: PLSE

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses growth accelerates

Q2 FY2026 operating expenses of $25.43M rose 27.1% year over year, ahead of the +15.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 32.6% from the prior quarter. Over 3 fiscal years it compounded at +17.4% a year.

Context

  • Operating expenses amounted to 21622.6% of revenue in FY2025.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +27.1% holds above the trailing-twelve-month pace of +15.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$25.43M+32.6% QoQ
Last fiscal yearDec 2025
$75.68M+34.5% YoY
LTMJun 2026
$82.79M+15.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.1%——
1 year+34.5%——
3-year CAGR+17.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
75.68M USD
Year-over-year change
+34.5%
4-year CAGR
+4.9%

Operating Expenses vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.0% is the 6th highest of 11, against a peer median of +17.9%.
  • Operating expenses amounts to 6986.2% of revenue for PLSE, versus a peer median of 173.8%.
PLSE Competitors
Operating Expenses for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$690.48M USD+6.8%+7.8%102.4%
OPKOPKO Health, Inc.LTM Mar 2026$334.91M USD-3.5%-12.3%57.6%
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
STAASTAAR Surgical CompanyLTM Apr 2026$226.94M USD-17.3%+8.3%78.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$219.67M USD+63.0%+70.8%11537.4%
LFMDLifeMD, Inc.LTM Mar 2026$201.37M USD-5.2%+4.1%91.8%
NKTRNektar TherapeuticsLTM Jun 2026$185.46M USD+13.6%-15.7%339.7%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$184.42M USD+91.1%—220.3%
ATAIAtai Beckley Inc.LTM Jun 2026$150.32M USD+82.4%-10.7%3360.6%
BBNXBeta Bionics, Inc.LTM Mar 2026$140.31M USD+52.4%+24.4%127.3%
PLSEPulse Biosciences, Inc.LTM Jun 2026$82.79M USD+15.0%+17.4%6986.2%
Peer median (excluding PLSE) —+17.9%+7.8%173.8%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.